BFRI · Biofrontera Inc.
$0.92
-0.10 (-9.37%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management believes that these conditions raise substantial doubt about the Company's ability to continue as a going concern for at least twelve months from the issuance date of this Quarterly Report on Form 10-Q.”View the 10-Q filed Aug 13, 2026
Market Cap
$16.19M
Shares
14.85M
Volume · Oct 5
573.11K
Avg daily vol (3M)
562.36K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.02
Open$1.11
Day$1.00–1.12
52W close$0.57–1.61
Avg vol 30d671K
Short int465K · 3.1% float · 1.0d
Short vol33%
Last earningsAug 13, 2026
DataOct 2021–Oct 2026
Filing10-Q · Aug 13
Up next
Next earnings call
Nov 13, 2026
Est · unconfirmed
· in 6 wks
filed Aug 13, 2026
call held May 14, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-2.4%
Trailing year
Short interest
3.1%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−1%
below
Price vs 50-day avg
−22%
below
RSI (14)
32
neutral
MACD trend
Negative
52-week position
43%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−33%
trailing
6-month return
−3%
trailing
YTD return
+78%
this year
Relative strength
−16%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow
Accumulating
+44% holders QoQ · +9 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.13% of float · ▲ +82.1% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
23 holders — near 3-yr high, broad support
Squeeze score
45
elevated · 0–100
Fundamentals
Revenue growth
+19%
Y/Y
EPS growth
+68%
Y/Y
Free cash flow
$-13.4M
Quant / Vol
risk profile
Volatility
81%
annualized · 1-yr
Max drawdown
−51%
past year
ATR
9.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Prior guidance
period ended
· from the 8-K filed Jan 13, 2026
Revenues
· fourth quarter ended December 31, 2025
$17M – $17.5M
Revenues
· full year 2025
$41.5M – $42M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−1%
Neutral
Price vs 50-day avg
−22%
Bearish
RSI (14)
32
Neutral
MACD trend
Negative
Bearish
52-week position
43%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow
Accumulating
+44% holders QoQ · +9 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.13% of float · ▲ +82.1% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
23 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1
Now $1 · 43%
Range high $2
vs 200-day avg -1%
vs 50-day avg -22%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -3.73M | Six Months Ended June 30 | — |
| Adjusted EBITDA margin non-GAAP | -16.9% | Six Months Ended June 30 | — |
| Cash used in operating activities | $1.7M | H1 2026 | — |
| EBITDA non-GAAP | -4.96M | Six Months Ended June 30 | — |
| Gross margin | 80% | H1 2026 | — |
| Stock-based compensation non-GAAP | 605K | Six Months Ended June 30 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BFRI
this stock
Biofrontera Inc.
|
$16.19M | +78.1% | +19.0% | — | 3.1% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$60.23B | +14.6% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$46.00B | -6.5% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$45.67B | +26.7% | +4.3% | 64.3 | 2.7% |
|
HLN
Haleon plc
|
$40.72B | -13.0% | — | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BFRI | -14.0% | -32.8% | -3.3% | -6.0% | +78.1% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -13.8% | -32.3% | -15.5% | -6.9% | +65.2% |